Citadel Advisors LLC boosted its stake in ChemoCentryx Inc (NASDAQ:CCXI) by 1,315.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 96,627 shares of the biopharmaceutical company’s stock after purchasing an additional 89,798 shares during the quarter. Citadel Advisors LLC owned about 0.20% of ChemoCentryx worth $1,273,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Federated Investors Inc. PA lifted its position in shares of ChemoCentryx by 23.7% in the 2nd quarter. Federated Investors Inc. PA now owns 66,569 shares of the biopharmaceutical company’s stock worth $877,000 after purchasing an additional 12,759 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of ChemoCentryx in the 2nd quarter worth approximately $4,232,000. BlackRock Inc. lifted its position in shares of ChemoCentryx by 6.0% in the 2nd quarter. BlackRock Inc. now owns 2,721,938 shares of the biopharmaceutical company’s stock worth $35,847,000 after purchasing an additional 155,172 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of ChemoCentryx in the 2nd quarter worth approximately $826,000. Finally, Swiss National Bank purchased a new stake in shares of ChemoCentryx in the 2nd quarter worth approximately $506,000. Institutional investors and hedge funds own 54.43% of the company’s stock.

Several equities research analysts have recently weighed in on CCXI shares. JPMorgan Chase & Co. cut shares of ChemoCentryx from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $14.00 to $15.00 in a research report on Tuesday, August 14th. Canaccord Genuity reaffirmed a “buy” rating and issued a $18.00 price target on shares of ChemoCentryx in a research report on Friday, August 10th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of ChemoCentryx in a research report on Monday, August 13th. B. Riley started coverage on shares of ChemoCentryx in a research report on Friday, September 7th. They issued a “neutral” rating and a $12.50 price target for the company. Finally, BidaskClub raised shares of ChemoCentryx from a “hold” rating to a “buy” rating in a research report on Thursday, August 30th. Six research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $16.58.

In other ChemoCentryx news, CFO Susan M. Kanaya sold 49,507 shares of the firm’s stock in a transaction on Thursday, June 28th. The shares were sold at an average price of $13.79, for a total value of $682,701.53. Following the completion of the transaction, the chief financial officer now owns 38,985 shares of the company’s stock, valued at $537,603.15. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Markus J. Cappel sold 25,179 shares of the firm’s stock in a transaction on Friday, June 29th. The stock was sold at an average price of $13.67, for a total transaction of $344,196.93. Following the completion of the transaction, the insider now directly owns 24,626 shares of the company’s stock, valued at approximately $336,637.42. The disclosure for this sale can be found here. Insiders have sold 76,436 shares of company stock valued at $1,050,371 in the last three months. 14.50% of the stock is currently owned by corporate insiders.

NASDAQ:CCXI opened at $11.09 on Thursday. ChemoCentryx Inc has a 52 week low of $5.42 and a 52 week high of $15.08. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.69 and a quick ratio of 2.69. The company has a market cap of $548.52 million, a P/E ratio of 32.82 and a beta of 1.37.

ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01. ChemoCentryx had a net margin of 18.69% and a return on equity of 39.31%. The company had revenue of $15.02 million during the quarter, compared to analysts’ expectations of $16.88 million. equities analysts anticipate that ChemoCentryx Inc will post -0.86 EPS for the current fiscal year.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).

Further Reading: Outstanding Shares

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.